Free Trial

Oruka Therapeutics Q1 2024 Earnings Report

Oruka Therapeutics logo
$9.91 -0.24 (-2.36%)
As of 03/3/2025 04:00 PM Eastern

Oruka Therapeutics EPS Results

Actual EPS
-$20.16
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Oruka Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Oruka Therapeutics Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

Oruka Therapeutics Earnings Headlines

Three new patents reveal Elon and Trump’s secret “Project America”
Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR! He says these 5 stocks are trading for less than $2 right now… But they could soon SOAR in Trump’s first 100 days.
Stifel Nicolaus Remains a Buy on Oruka Therapeutics (ORKA)
See More Oruka Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oruka Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oruka Therapeutics and other key companies, straight to your email.

About Oruka Therapeutics

Oruka Therapeutics (NASDAQ:ORKA) is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

View Oruka Therapeutics Profile

More Earnings Resources from MarketBeat